Authors: Jade Parker, Editor
The FDA has expanded the label for AstraZeneca’s oral PARP inhibitor Lynparza (olaparib) to include the treatment of patients with metastatic breast cancer whose disease is associated with a BRCA gene mutation.
The decision makes olaparib the first and only approval for a PARP inhibitor for use beyond ovarian cancer. It is the first time any drug has been approved specifically to treat BRCA-mutated breast cancer.
The approval is a result of the highly promising results published from the